Literature DB >> 17687191

Mechanistic analysis of VDR-mediated renin suppression.

Masaki Nakane1, Junli Ma, Xiaoan Ruan, Paul E Kroeger, Ruth Wu-Wong.   

Abstract

BACKGROUND: The vitamin D receptor (VDR) is involved in the regulation of renin expression and vitamin D analogs down-regulated renin mRNA expression in As4.1 cells.
METHODS: Microarray analysis was used to assess the VDR-mediated gene expression profile in As4.1 cells treated with paricalcitol, followed by real-time RT-PCR. Mechanistic analyses were done using siRNA, electrophoretic mobility shift assay (EMSA) and Western blotting.
RESULTS: Microarray analysis shows that 709 target genes were affected by paricalcitol with 286 up- and 423 downregulated. A number of major pathways were impacted including transcription factors. Real-time RT-PCR confirmed the microarray results. Treatment of the cells with siRNA against nuclear receptor co-repressor (NCOR1) eliminated VDR-mediated renin suppression. Using EMSA, paricalcitol treatment reduced the level of protein complex binding to the cyclic AMP-responsive element (CRE)-like domain in the renin distal enhancer region. VDR, CRE-binding protein (CREB1) and NCOR1 were identified in the complex binding to the CRE-like domain by Western blot in the paricalcitol-treated cells. Paricalcitol treatment resulted in an increase in the VDR level, but no significant change in the CREB1 and NCOR1 levels.
CONCLUSION: These results suggest that VDR-mediated renin suppression likely acts through a transcriptional regulatory complex including CREB1, NCOR1 and VDR that binds to the CRE-like domain in the renin enhancer region. (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17687191     DOI: 10.1159/000106792

Source DB:  PubMed          Journal:  Nephron Physiol        ISSN: 1660-2137


  8 in total

Review 1.  Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.

Authors:  Katherine Wesseling-Perry; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2013-02-05       Impact factor: 3.714

Review 2.  Potential for vitamin D receptor agonists in the treatment of cardiovascular disease.

Authors:  J R Wu-Wong
Journal:  Br J Pharmacol       Date:  2009-04-09       Impact factor: 8.739

Review 3.  Control of renin [corrected] gene expression.

Authors:  Sean T Glenn; Craig A Jones; Kenneth W Gross; Li Pan
Journal:  Pflugers Arch       Date:  2012-05-11       Impact factor: 3.657

4.  The use of vitamin D analogues in chronic kidney diseases: possible mechanisms beyond bone and mineral metabolism.

Authors:  Cheuk-Chun Szeto; Philip Kam-Tao Li
Journal:  NDT Plus       Date:  2009-03-24

5.  Vitamin D depletion aggravates hypertension and target-organ damage.

Authors:  Louise Bjørkholt Andersen; Lukasz Przybyl; Nadine Haase; Frauke von Versen-Höynck; Fatimunnisa Qadri; Jan Stener Jørgensen; Grith Lykke Sorensen; Palle Fruekilde; Marko Poglitsch; István Szijarto; Maik Gollasch; Joerg Peters; Dominik N Muller; Henrik Thybo Christesen; Ralf Dechend
Journal:  J Am Heart Assoc       Date:  2015-01-28       Impact factor: 5.501

6.  Identification of genetic variants affecting vitamin D receptor binding and associations with autoimmune disease.

Authors:  Giuseppe Gallone; Wilfried Haerty; Giulio Disanto; Sreeram V Ramagopalan; Chris P Ponting; Antonio J Berlanga-Taylor
Journal:  Hum Mol Genet       Date:  2017-06-01       Impact factor: 6.150

7.  EFFECT OF ASTRAGALOSIDE ON VITAMIN D-RECEPTOR EXPRESSION AFTER ENDOTHELIN-1-INDUCED CARDIOMYOCYTE INJURY.

Authors:  Chen Yunzhi; Chen Jiaxu; Gao Jie; Chai Yihui; Li Wen; Qin Zhong
Journal:  Afr J Tradit Complement Altern Med       Date:  2017-06-05

8.  Modulation of cardiometabolic risk and CardioRenal syndrome by oral vitamin D3 supplementation in Black and White Southern Sahara residents with chronic kidney disease Stage 3: focus on racial and ethnic disparities.

Authors:  Asma Bouazza; Amina Tahar; Samir AitAbderrhmane; Messaoud Saidani; Elhadj-Ahmed Koceir
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.